Completed PHASE2 INTERVENTIONAL 1-arm NCT00557102

Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung (ERBIFORT)

Frontline Chemotherapy Reinforced for Cancers of the Colon and Rectum With Potentially Resectable Hepatic and/or Pulmonary Metastases: Association of FOLFIRI and ERBITUX

Sponsor: National Cancer Institute, France

Conditions Colorectal Cancer Metastatic Cancer

Interventions cetuximab filgrastim fluorouracil irinotecan hydrochloride leucovorin calcium

Updated 5 times since 2017 Last updated: Dec 10, 2012 Started: Sep 30, 2007 Primary completion: Dec 31, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00557102, this PHASE2 trial focuses on Colorectal Cancer and Metastatic Cancer and remains completed. Sponsored by National Cancer Institute, France, it has been updated 5 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute, France
University Hospital, Grenoble

Data source: National Cancer Institute, France

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Grenoble, France